Innova Captab FY26 Revenue Grows 31% to ₹1,630 Cr Amid Major Expansion Plans

Innova Captab Ltd reported strong financial results for fiscal year 2026, with consolidated revenue reaching ₹1,630 crore. This represents a significant 31% increase year-over-year from ₹1,244 crore in FY25.

The company's Profit After Tax (PAT) for the full year rose 10% to ₹140.9 crore.

Performance in the fourth quarter (Q4 FY26) was particularly strong, with revenue jumping 42% to ₹447.8 crore and PAT growing 29% to ₹38.1 crore. Growth drivers included the Contract Development and Manufacturing Organisation (CDMO) business, up 24%, and the Branded Generics segment, which saw an impressive 51% increase.

Growth Drivers and Strategy

The company's expansion strategy is central to its growth outlook. Innova Captab plans to invest ₹150-170 crore over FY27-28 to build a new manufacturing facility in Baddi. This expansion is expected to significantly increase production capacity, particularly for its general product portfolio.

A key focus is also on enhancing its presence in regulated markets. The company is working towards certifications like EU-GMP and PIC/S, which are anticipated to open up higher-value export opportunities in markets like Europe and the United States.

The Jammu manufacturing facility is nearing EBITDA positivity, indicating improved operational efficiency and a move towards profitability for that site.

Impact for Investors

These developments signal potential benefits for shareholders. Increased manufacturing capacity from the Baddi facility is expected to drive higher revenue streams.

Success in obtaining regulatory certifications for international markets could diversify revenue sources and improve overall profit margins.

The progress at the Jammu facility toward EBITDA positivity suggests better operational performance and a positive contribution to the company's financial results.

Risks to Watch

While the CDMO business's cost-plus model helps pass on rising API costs, global supply chain disruptions and geopolitical factors remain potential challenges.

The successful and timely execution of the Baddi expansion project within budget will be critical for sustaining future growth.

Securing and maintaining regulatory certifications for key international markets requires ongoing compliance and investment.

Peer Comparison

Innova Captab operates in a competitive landscape. Key Indian pharmaceutical players like Syngene International and Divi's Laboratories are also investing heavily in expanding their CDMO and API capacities.

Leaders in branded generics, such as Sun Pharmaceutical Industries, are focused on global market expansion and product portfolio growth.

These peers are also prioritizing investments in regulated markets and operational efficiency to drive growth.

What to Track Next

Investors will be monitoring the Jammu facility's progress towards sustained EBITDA positivity.

Track the timely completion and ramp-up of the new Baddi manufacturing facility.

Observe continued growth in both the CDMO and Branded Generics segments, along with market penetration in regulated markets.

Developments related to international market performance and the acquisition of new regulatory certifications are also crucial.